Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of different doses of caspofungin in invasive aspergillosis
ChiCTR2300074819Phase 4Not yet recruiting
- Sponsor
- The Peoples' Hospital of Jiaozuo City
- Start
- Sep 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of caspofungin in invasive aspergillosis (IA) (4 arms), sponsored by The Peoples' Hospital of Jiaozuo City. Primary endpoint: Evaluate efficacy. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on ChiCTR2300074819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074819.